SCREENING OF CLOTTING SYSTEM DISORDERS BY LABORATORY TESTS
https://doi.org/10.15829/1560-4071-2015-3-52-57
Abstract
The review takes into consideration the diagnostic significance of the main screening coagulologic tests under the light of modern views on the role of vessel wall, plasma proteins and blood cells in the dynamics of thrombin formation and its activities regulation.
About the Authors
A. B. Dobrovolsky
FSBI Russian Cardiological Scientific-Production Complex of HM RF, Moscow
Russian Federation
Russian Federation
E. V. Titaeva
FSBI Russian Cardiological Scientific-Production Complex of HM RF, Moscow
Russian Federation
Russian Federation
References
1. Mann KG, Brummel K, Butenas S . What is all that thrombin for? J Thromb Haemost 2003; 1: 1504-14.
2. Crawley JTB, Zanardelli S, Chion CKNK, et al.The central role of thrombin in hemostasis. J T hromb Haemost 2007; 5: 95-101.
3. Furie B., Furie B. C. Mechanisms of Thrombus Formation. N Engl J Med 2008; 359: 938-49.
4. Maureen McMichael. New Models of Hemostasis. Topics in Companion An Med 27 (2012) 40-45.
5. Versteeg HH, Heemskerk JWM, Levi M, et al. New Fundamentals in Hemostasis. Physiol Rev 2013; 93: 327-58.
6. Butenas S, Mann KG. Blood coagulation (review). Biochemistry (Moscow) 2002; 67: 5-15. Russian (Бутенас С ., Манн КГ. Свертывание крови (обзор). Биохимия 2002, 67, 5-15).
7. Di Nisio M, Baudo F, Cosmi B, et al. on behalf of the Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2011doi: 10.1016/j.thormbres.2011.08.028.
8. Kaptoge S ., Di Angelantonio E., Pennells L. The Emerging Risk Factors Collaboration. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. N Engl J Med. 2012; 367(14): 1310-20.
9. Ariens R. A.S. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (Suppl. 1) 294-305.
10. Turpie A. G .G., Esmon C. Venous and arterial thrombosis — pathogenesis and the rationale for anticoagulation. Thromb Haemost 2011; 105: 586-96.
11. Mahmoodi BK, Brouwer JL, Veeger NJ, et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118: 1659-67.
12. Kenet G, Lütkhoff LK, Albisetti M, et al. Impact of thrombophilia on risk or arterial stroke or cerebral sinovenous thrombosis in neonates and children: A systematic review and metaanalysis of observational studies. Circulation 2010; 121: 1838-47.
13. Yilmaza S, Gunaydin S . Inherited risk factors in low-risk venous thromboembolism in patients under 45 years. Interactive CardioVascular and Thoracic Surgery 2015; 20: 21-3.
14. Keeling D . Thrombophilia screening or screaming. J Thromb Haemost 2010; 8: 1191-2.
15. Lijfering WM, Brouwer J-LP, Veeger NJGM, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009; 113: 5314-22.
16. Ruff CT, Giugliano RP, Braunwald E. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2013; published online Dec 4. http://dx.doi.org/10.1016/ S0140-6736(13)62343-0.
17. Pabinger I, Vossen CY, Lang J, et al. Mortality and Inherited Thrombophilia: results from the European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2012; 10: 217-22.
18. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-61.
19. Righini M, Perrier A, De Moerloose P, et al. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008; 6: 1059-71.
20. Dobrovolsky AB, Titaeva EV. Haemostatic risk factors of thrombosis and laboratory control of anticoagulant therapy. Atherothrombosis 2009; 2 (1): 2-14. Russian (Добровольский А. Б ., Титаева Е. В. Коагулогические факторы риска тромбозов и лабораторный контроль антикоагулянтной терапии. Атеротромбоз, 2009, 2, 1, 2-14).
21. Vorobyeva NM, Panchenko EP, Dobrovolskyi AB, et al. Factors associated with D-dimer elevation in patients with venous thromboembolic events. Russ J Cardiol 2012; 4(96): 18-24. Russian (Воробьёва Н. М., Панченко Е. П., Добровольский А. Б ., и др. Факторы, ассоциирующиеся с повышением Д-димера у больных венозными тромбоэмболическими осложнениями. Российский кардиологический журнал 2012; 4(96): 18-24).
22. de Bastos MRD, Bogutchi T, Carneiro-Proietti ABF, et al. Duration of symptoms and D-dimer testing in the ruling-out of venous thromboembolism. J Thromb Haemost 2006; 4: 2079-80.
23. Vorobjeva NM, Panchenko EP, Dobrovolskii АВ, Titaeva EV. Elevated D-dimer in patients with cardiovascular diseases free from thromboembolic complications: what is it associated with and what has to be done? Angiology and Vascular Surgery 2010; 16 (4): 34-42. Russian (Воробьёва Н. М., Панченко Е. П., Добровольский А. Б ., Титаева Е. В. Повышение Д-димера у больных сердечно-сосудистыми заболеваниями без тромбоэмболических осложнений: с чем это связано и что делать? Ангиология и сосудистая хирургия 2010; 16 (4): 34-42).
24. Douma RA, Tan M, Schutgens REG, et al. Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica 2012; 97(10): 1507-13.
25. Palareti G, Cosmi B, Legnani C, et al. for the PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-9.
26. Eichinger S, Heinze G, Jandeck LM, et al. Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism. The Vienna Prediction Model. Circulation 2010; 121: 1630-6.
27. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J T hromb Haemost 2012; 10: 1019-5.
28. Lowe G, Rumley A. The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us? Thromb Haemost 2014; 112: 860-7.
29. Christersson C, Wallentin L, Andersson U, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation — observations from the ARISTOTLE trial. J Thromb Haemost. 2014; 12: 1401-12.
30. Castelnuovo A, Agnoli C, de Curtis A, et al. Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke Findings from the EPICOR Study. Thromb Haemost 2014; 112: 941-6.
Review
For citations:
Dobrovolsky A.B., Titaeva E.V. SCREENING OF CLOTTING SYSTEM DISORDERS BY LABORATORY TESTS. Russian Journal of Cardiology. 2015;(3):52-57. (In Russ.) https://doi.org/10.15829/1560-4071-2015-3-52-57
Views:
1057
Email this article 